Role of sildenafil citrate therapy in pregnant women with foetal growth restriction and oligohydrominos from Northern India


  • Priyanka Joshi Department of Obstetrics and Gynecology, Rabindra Nath Tagore Medical College, Udaipur, Rajasthan, India
  • Madhubala Chouhan Department of Obstetrics and Gynecology, Rabindra Nath Tagore Medical College, Udaipur, Rajasthan, India
  • Nidhi Choudhary Department of Obstetrics and Gynecology, Rabindra Nath Tagore Medical College, Udaipur, Rajasthan, India
  • Abhishek Singh Department of Community Medicine, SHKM Government Medical College, Mewat, Haryana, India



Intrauterine growth restriction/oligohydramnios, Perinatal outcome, Sildenaphil citrate therapy


Background: No specific treatment is available for severe early-onset IUGR. To best of my knowledge, very few studies have assessed the potential benefit of Sildenafil therapy targeted to improve perinatal outcomes in pregnancies complicated by severe early-onset IUGR in Indian pregnant women.

Methods: The present hospital based prospective study was carried out on one hundred ANC pregnant women with early and late fetal growth restriction and oligohydrominos at Pannadhai Mahila Chikatsalya, Rabindra Nath Tagore (RNT) Medical College, Udaipur, during Jan to Dec 2017. Sildenafil citrate 25 mg three times in a day was  administered until delivery. Study subjects were subjected to fetal Doppler and ultrasound twice a week after the Sildenafil administration.

Results: After sildenafil therapy, out of total 45 cases of IUGR alone, 39 cases (86.66 %) had improvement. Out of 35 cases of oligohydramnios alone, 28 cases (80 %) had improvement.  Out of 20 cases having both IUGR and Oligohydramnios 16 had improvement (80 %) and only 4 cases did not show any improvement. Among gestation age 27-30 weeks group at the time of admission, there were total 10 cases out of which 5 (50 %) had early premature delivery (32-34 weeks), 3 (30 %) had late premature delivery (34-37 weeks) and 2 cases (2 %) had term delivery i.e. between 37-39 weeks after giving sildenafil treatment.

Conclusions: The findings of the present study indicate that sildenafil citrate may offer a potential therapeutic strategy to improve outcomes in pregnant women facing foetal growth restriction and oligohydrominos.


Murki S, Sharma D. Intrauterine growth retardation: A review article. J Neonatal Biol. 2014;3(135):2167-897.

Froen JF, Gardosi JO et al. Restricted fetal growth in sudden intrauterine unexplained death. Acta Obstet Gynecol Scand. 2004;83(9):801-7.

Richardus JH, Graafmans WC, et al. Differences in perinatal mortality and suboptimal care between 10 European regions: results of an international audit BJOG 2003;110(2):97-105.

Petersen SG, Wong SF, Urs P, Gray PH, Gardener GJ. Early onset, severe fetal growth restriction with absent or reversed end- diastolic flow velocity waveform in the umbilical artery: perinatal and long-term outcomes. Aust NZ J Obstet Gynaecol 2009;49(1):45-51.

Bilardo CM, Wolf H, Stigter RH, Ville Y, Baez E, Visser GH, et al. Rela- tionship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gyne- col 2004;23(2):119-25.

Olofsson P, Laurini RN, Marsál K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol. 1993;49(3):161-8.

Sağol S, Sağol O, Ozdemir N. Stereological quantification of placental villus vascularization and its relation to umbilical artery Doppler flow in intrauterine growth restriction. Prenat Diagn. 2002; 22(5):398-403.

Von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL. Sildenafil citrate therapy for severe early‐onset intrauterine growth restriction. BJOG: Int J Obstet Gynaecol. 2011;118(5):624-8.

Dastjerdi MV, Hosseini S, Bayani L. Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. J Res Med Sci. 2012;17(7):632-6.

Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fet Diagnos Ther. 2017;41(2):81-8.

Miller SL, Loose JM, Jenkin G, Wallace EM. The effects of sildenafil citrate (Viagra) on uterine blood flow and wellbeing in the intrauterine growth-restricted fetus. Am J Obstet Gynecol. 2009;200(1):102-e1.

Maged M, Wageh A, Shams M, Elmetwally A. Use of sildenafil citrate in cases of intrauterine growth restriction (IUGR); a prospective trial. Taiwanese J Obstet Gynecol. 2018;57(4):483-6.

Premalatha HL, Raghupathi KMS, Srinivas DNB, Venkatesh, Laxmi Kanth. Study of effect of sildenafil citrate in pregnant women with intrauterine growth restriction/ oligohydramnios. Int J Reprod Contracept Obstet Gynecol. 2016;5(9):3094-7.

Singh A, Daharwal A, Kujur A, Awasthi P. Effect of sildenafil on IUGR. Int J Reprod Contracept Obstet Gynecol 2017;6(5):1806-9.

Panda S, Das A. Sildenafil Citrate in Fetal Growth Restriction. J Reprod Infertil. 2014;15(3):168-9.

Ferreira E, Léveillée D, Iglesias MH, Brochet MS. O-OBS-MFM-PhD-065 Sildenafil Use During Pregnancy for Intrauterine Growth Restriction: A Case Series. J Obstet Gynaecol Canada. 2016;38(5): 486.






Original Research Articles